Roflumilast Boosts Semaglutide's cAMP Response, Extending Weight-Loss Effects

Blocking PDE4 with roflumilast kept cAMP high in area postrema neurons, suggesting a way to prolong semaglutide’s appetite‑suppressing signal.

Unpacking the Neuronal Response

Semaglutide, a GLP‑1 receptor agonist, activates GLP‑1R‑expressing neurons in the hindbrain’s area postrema. Using fluorescence imaging in live mouse tissue, researchers observed that cAMP levels rose in a continuum across individual neurons. Some cells maintained elevated cAMP for hours, while others only showed transient spikes—likely because they internalized or degraded their receptors. The variability explained why patients experience differing weight‑loss responses and why most eventually hit a plateau.

PDE4 Inhibition as a Potentiator

The team inhibited phosphodiesterase 4 (PDE4), the enzyme that breaks down cAMP, with the drug roflumilast. This manipulation shifted the population of neurons toward a sustained cAMP response. By keeping the appetite‑suppressing signal active longer, roflumilast could reduce how often GLP‑1 drugs need to be administered. The authors cautioned that translating this to humans will require studies over days and weeks, beyond the hours the current imaging can capture.

Implications for GLP‑1 Therapy

If PDE4 inhibition can reliably extend semaglutide’s effect, combination therapy might break the weight‑loss plateau that plagues many patients. The findings also point to intracellular cAMP modulation as a new target for drug development. Future work will need to test roflumilast or other PDE4 inhibitors in chronic settings and assess safety, efficacy, and dosing schedules.

The study, led by Claire Gao, Ph.D., and co‑corresponding authors Andrew Lutas and Michael Krashes, appears in Nature Metabolism (2026) (DOI: https://www.nature.com/articles/s42255-026-01534-8).

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov